Bivamelagon is a melanocortin receptor agonist.

Turbinaric acid is a moderately cytotoxic secosqualene carboxylic acid that is isolated from the brown alga Turbinaria ornata.

IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research.

T-10418 is a potent and selective G2A agonist with EC50 of 0.82 μM. T-10418 exhibits higher potency than the reference and natural ligand 9-HODE and high selectivity among G protein-coupled receptors. T-10418 is a suitable candidate for in vivo studies on therapeutic potential of G2A agonism.

TG6A is a biodegradable and ionizable glycerolipid for cmRNA delivery. TG6A-LNP exhibits above 9-fold and 41-fold higher EGFP protein expression in MSCs than DLin-MC3-DMA-LNP and ALC-0315-LNP, respectively.

AZ'9567 is a potent inhibitor of MAT2A with pIC50 of 8.2. in vitro with excellent preclinical pharmacokinetic properties. AZ'9567 shows robust antitumor response in the MTAP KO HCT116 model.

LL-K12-18 is a dual-site molecular glue for CDK12-DDB1 complex with EC50 of 0.37 nM. LL-K12-18 shows an 80-fold enhanced potency than SR-4835 in MDA-MB-231 cells and with a 307-fold boost potency (EC50 = 0.03 nM) in MDA-MB-468 cells, while the degradation efficiency (DC50 = 0.38 nM) increased 50-fold.

DS18 is a DDB1-CDK12 molecular glue with EC50 of 8.771 nM.

Lipid A1-D1-5 is an ionizable lipid-like substance used for RNA interference therapy in heat-stable ionizable lipid-like nanoparticles (iLAND) for the treatment of hyperlipidemia.

GlyRS-IN-1 is a glycyl-tRNA synthase (GlyRS) inhibitor extracted from patent WO 2017066459 A1. GlyRS-IN-1 can also inhibit the growth of bacteria.

GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation.

AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor.

(+)-UH 232 is a partially selective agonist of the D3 receptor with an intrinsic activity of 0.2-0.4. (+)-UH 232 antagonized quinpirole-induced mitogenesis with a Ki value of 9.4 nM.

Bartsioside is an anti-inflammatory agent which can be extracted from C. deserticola. Bartsioside exerts no significant cytotoxicity under 40 μM to BV-2 cells.

BLU-222 is an investigational, oral, potent, and selective CDK2 inhibitor. BLU-222 has shown robust anti-tumor activity in preclinical models of CCNE-aberrant ovarian, breast and gastric cancer.

Gepotidacin, also known as GSK-2140944, is a potent Type II DNA topoisomerase inhibitor. Gepotidacin is a novel antibacterial drug candidate. Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats. Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively.

TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation.

VVD-130037 is an oral covalent activator of KEAP/NRF2 degrader.

BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research.

Acid-degradable Cationic Lipid (ADC) composed of cationic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

BI-9508 is a potent and selective, brain-penetrant GPR88 agonist with EC50 of 47 nM.

Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.

Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Br is an ADC linker that can be used to synthesize ABBV-154, ABBV-927, ABBV-368 or their analogs.

Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.

Mal-amido-PEG6-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Val-Ala-PAB is a cleavable ADC linker that can be used for ADCs synthesis.

Fomc-Gly-Gly-Phe-Gly-OH (compound D5) can be used as an intermediate in the synthesis of ADC dual-drug-linker. Fomc-Gly-Gly-Phe-Gly-OH synthetic intermediate GGFGE further forms an important ADC dual-drug link assembly unit.

Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation.

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections.

Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections.

Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research.

Afelimomab (MAK 195F) is an anti-tumor necrosis factor F(ab')2 monoclonal antibody fragment. Afelimomab can be used for the research of sepsis.

Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis.

Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).

Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493).

Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.

IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6+ ovarian and testicular cancer cell lines.

Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma.

Dinotefuran UF is the deuterium labeled γ-Tocotrienol. γ-Tocotrienol is an active form of vitamin E

ICA-1S is a potent, specific inhibitor of Protein Kinase C-iota (PKC-ι), does not inhibit PKC-ζ, the closely related atypical PKC family member.

Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

Acid-degradable Anionic Lipid (ADA) composed of anionic lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

LI-3948 is a blood-brain barrier penetrant inositol hexakisphosphate kinase (IP6K) inhibitor with IC50 of 16 nM and brain/plasma ratio of 1.3, respectively.

Lipid CP-LC-1143 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

Lipid CP-LC-1254 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

CP-LC-0729 is an ionizable lipid that significantly surpasses the MC3 in protein expression while showing no in vivo toxicity. CP-LC-0729 demonstrates a very high selectivity to lungs with a remarkable 32-fold increase in protein expression compared to MC3.

Lipid CP-LC-0743 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

Lipid CP-LC-0867 is an ionizable cationic amino lipid derived from homocysteine, a naturally occurring amino acid. This lipid has demonstrated an efficient delivery and high protein expression of different kinds of RNA (mRNA, cRNA and saRNA) in vivo, with no signs of toxicity.

C9-200 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing C9-200 and encapsulating mRNA encoding erythropoietin (EPO) increase serum EPO levels in mice. LNPs containing C9-200 and encapsulating mRNA encoding the Cas9 nuclease and small-guide RNA (sgRNA) targeting transthyretin (TTR) induce 3-fold higher hepatic insertion and deletion (indel) formation than LNPs containing C12-200 (Item No. 36699) and encapsulating mRNA encoding Cas9 in mice.

Lipid N2-3L is an ionizable cationic lipid (pKa = 8.99) that has been used in the generation of supramolecular lipid nanoparticles (SMLNPs) encapsulating mRNA for use in vitro and in vivo.1 SMLNPs containing lipid N2-3L and encapsulating a luciferase reporter accumulate at the site of injection and in the draining lymph nodes of mice. Lipid N2-3L-containing SMLNPs encapsulating ovalbumin mRNA and the toll-like receptor 7/8 (TLR7/8) agonist R-848 (Item No. 14806) as an adjuvant promote dendritic cell maturation and antigen presentation, reduce tumor volume, and increase survival in an MC-38-OVA murine model of colon cancer.

YHS-12 is an ionizable cationic lipid (pKa = 6.506) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.1 LNPs containing YHS-12 and the macrophage targeting peptide CRVLRSGSC and encapsulating mRNA encoding chimeric antigen receptor targeting methicillin-resistant S. aureus (MRSA) and siRNA targeting caspase-11 increase the phagocytosis rate of MRSA in RAW 264.7 macrophages and primary mouse bone marrow-derived macrophages (BMDMs). Intravenous administration of these LNPs decreases blood bacterial burden and increases survival in a model of sepsis using cyclophosphamide-induced immunosuppressed mice.

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.

Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis.

Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis.

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy.

Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985)).

Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors.

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells.

Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases.

Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD).

Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies.

Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia.

Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research.

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.

Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC).

Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency.

Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research.

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research.

Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .

(R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 is the 13C-labeled (R)-2-Thioxothiazolidine-4-carboxylic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified.

STING agonist-12 (Compound 53) is a potent, orally active human STING activator with an EC50 of 185 nM.

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

(S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R).

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer.

Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.

CD-005 is a low-molecular-weight gelator that can be used to prepare gels for proteins and vaccines. CD-005 can physically entrap proteins, preventing their irreversible aggregation, and maintain protein function for at least 4 weeks even at temperatures up to 50°C.

Casdatifanum is a hypoxia-inducible factor (HIF) inhibitor.

BMS-986408 is a DGK inhibitor.

BAY-2925976 is an ARα2C antagonist.

AZD4144 is an NLRP3 inhibitor.

CHF-6523 is an inhaled PI3Kδ inhibitor.

Compound 33 (HYOU1 inhibitor) is a first-in-class inhibitor of hypoxia up-regulated protein 1 (HYOU1) with EC50 of 3.2 μM/2.6 μM/16.1 μM/3.0 μM in WT-MIP3/WT-RANTES/hTNFtg-MIP3/hTNFtg-RANTES, respectively.

BRD-810 is a potent and selective MCL1 inhibitor with Kd of 0.3 nM (SPR) and IC50 of 0.4 nM (MCL1-Noxa HTRF), respectively. BRD-810 is a rapidly cleared inhibitor of MCL1 that has robust antitumor efficacy in hematological and solid tumor cancer models.

ERAS-0015 is a pan-RAS modulator glue and demonstrates siganificantly more potent inhibition of cellular proliferation across KRAS mutant cell lines vs RMC-6236.

CBPD-409 is a highly potent, selective and orally bioavailable PROTAC degrader of CBP/p300. CBPD-409 induces robust CBP/p300 degradation with DC50 0.2-0.4 nM and displays strong antiproliferative effects with IC50 1.2-2.0 nM in the VCaP, LNCaP, and 22Rvl AR+ prostatcancer cell lines.

GSDMD agonist DMB is a direct and selective gasdermin D (GSDMD) agonist, activates GSDMD pore formation to trigger liposome leakage with EC50 of 0.7 uM, activates GSDMD pore formation and pyroptosis without cleaving GSDMD. DMB directly binds to GSDMD by microscale thermophoresis (MST) with a dissociation constant (KD) of 1.1 uM. DMB induces pyroptosis in immortalized and primary cells in a GSDMD-dependent and cleavage-independent manner. DMB binds to GSDMD and induces cleavage-independent GSDMD oligomerization and pore formation. activated human GSDMD but not other human gasdermins, also activates mouse GSDMD in the liposome leakage assay, albeit with ∼5-fold reduced efficacy. GSDMD agonist DMB modifies GSDMD at C191, which is conserved in GSDMD from different species but not in other gasdermin family members. DMB induces tumor regression and enhances antitumor immunity that depends on GSDMD expression in the tumor.

HSPC is a natural product. Hydrogenated soya phosphatidylcholines can extend drug release in regard to drug loading and solubility for oral drug delivery of watersoluble drugs.

Sodium stearyl fumarate can be used as an excipient. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs.

Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways.

L-Lysine hydrate is an essential amino acid. L-Lysine hydrate can be research for vascular calcification (VC) and acute pancreatitis.

DL-alpha-Tocopherol is a synthetic vitamin E, with antioxidation effect. DL-alpha-Tocopherol protects human skin fibroblasts against the cytotoxic effect of UVB.

Lauroylsarcosine sodium is a surfactant commonly used in personal care and cosmetics such as shampoos, facial cleansers and toothpaste. It works by lowering the surface tension of water, allowing it to better penetrate and clean surfaces. Lauroylsarcosine sodium is considered safe for cosmetic use and is approved for use in several countries. However, it can cause skin irritation in high concentrations or with prolonged exposure.

Isopropyl stearate (Stearic acid,isopropyl ester) is an ester product.

Ethyl Oleate is a fatty acid ester formed by the condensation of oleic acid and ethanol. Ethyl oleate is the liquid lipid component in nanostructured lipid carriers (NLCs). NLC is a promising vehicle for oral trans-Ferulic acid (TFA) administration.

Gentisic acid ethanolamide is a complexing agent in pharmaceutical parenterals. It is used as a solubilizer in some pharmaceutical preparations and as an antiseptic agent.

Acetyltriethyl citrate is a biochemical.

Polyquaternium-1 (Polidronium chloride) is a polycationic ophthalmic preservative. Polyquaternium-1 can inhibit growth of microbial contaminants in multi-dose bottles of topical medications.

Cholesteryl sulfate sodium is an important regulatory molecule. Cholesterol sulfate sodium is a component of cell membranes where it has a stabilizing role and protects erythrocytes from osmotic lysis and regulating sperm capacitation.

Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide.

α-Lactose (hydrate) (α-D-Lactose (hydrate)) is the principal carbohydrate in the milk of most mammals. α-Lactose (hydrate) consists of glucose and galactose and exists in the form of two anomers, α and β. α-Lactose (hydrate) has many uses in the food and pharmaceutical industries, such as a free-flowing or agglomerating agent, a diluent for pigments, flavors, or enzymes.

Doxacurium chloride (BW A938U) is a potent non-depolarizing neuromuscular blocking agent. Doxacurium chloride binds to cholinergic receptors to antagonize acetylcholine, resulting in a block of neuromuscular transmission. Doxacurium chloride can be used for the research of neurological diseases.

AZ'3137 is an orally bioavailable androgen receptor (AR) degrader that recruit the Cereblon (CRBN) E3 ligase with DC50 of 22 nM (LNCaP) and 92 nM (LNCaP L720H), respectively.

CB31 is a highly potent and orally bioavailable PD-L1 inhibitor with IC50 of 0.2 nM (PD-1/PD-L1 alphs) and EC50 of 15 nM (NFAT), with high passive permeability, good metabolic stability and favorable oral PK. CB31 targets both the surface and intracellular PD-L1, reducing tumor size and killing cells in a 3D spheroid model.

Compound 13 (MET inhibitor) is a selective, potent, and mutant-active MET inhibitor with a MET D1228N cell line IC50 of 23 nM and shows good efficacy in the MET-D1228N Type I resistance mutation model.

A-910 is a orally bioavailable, highly potent and selective dual MerTK/Axl inhibitor with IC50 of 0.3 nM/0.8 nM. A-910 exhibits favorable oral bioavailability, exceptional kinome selectivity, and significantly improved in MerTK Ba/F3 xenograft tumor model.

R1-ICR-5 is a highly selective and efficacious PROTAC degrader of both human and murine RIPK1.

Compound 12f (LPA1 antagonist) is a potent and highly selective LPA1 antagonist with IC50 of 16.0 nM (cAMP assay) and 18.4 nM (calcium mobilization assay), respectively.

Semaglutide acetate, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide acetate has the potential for type 2 diabetes treatment.

Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes.

Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers.

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.

Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells.

Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers.

Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy.

Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake.

Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease.

Cbl-b-IN-10 (Compound 463) is a casitas B-lineage lymphoma-b (Cbl-b) and c-Cbl inhibitor with IC50s of 6.0 nM and 3.5 nM, respectively.

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.

Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.

Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.

Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.